These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32433815)

  • 1. Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index.
    Touma Z; Gladman DD; Zandy M; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1243-1249. PubMed ID: 32433815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.
    Touma Z; Gladman DD; Su J; Anderson N; Urowitz MB
    Rheumatology (Oxford); 2018 Aug; 57(8):1370-1376. PubMed ID: 29688532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.
    Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD
    Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
    J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLEDAI-2K for a 30-day window.
    Touma Z; Urowitz MB; Gladman DD
    Lupus; 2010 Jan; 19(1):49-51. PubMed ID: 19910390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.
    Ibañez D; Urowitz MB; Gladman DD
    J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
    Sato JO; Corrente JE; Saad-Magalhães C
    Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.
    Touma Z; Urowitz MB; Ibañez D; Gladman DD
    Lupus; 2011 Jan; 20(1):67-70. PubMed ID: 21233149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years.
    Touma Z; Gladman DD; Ibañez D; Urowitz MB
    Lupus; 2012 Oct; 21(12):1305-11. PubMed ID: 22800940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement.
    Touma Z; Gladman DD; Su J; Ibañez D; Urowitz MB
    J Rheumatol; 2015 Aug; 42(8):1401-5. PubMed ID: 26077403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.
    Fatemi A; Raeisi A; Sayedbonakdar Z; Smiley A
    Clin Rheumatol; 2018 Apr; 37(4):955-962. PubMed ID: 29256112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients.
    Jesus D; Rodrigues M; Matos A; Henriques C; Pereira da Silva JA; Inês LS
    Lupus; 2019 Apr; 28(5):607-612. PubMed ID: 30895904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis.
    Ruiz-Arruza I; Barbosa C; Ugarte A; Ruiz-Irastorza G
    Autoimmun Rev; 2015 Oct; 14(10):875-9. PubMed ID: 26044819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
    Jesus D; Matos A; Henriques C; Zen M; Larosa M; Iaccarino L; Da Silva JAP; Doria A; Inês LS
    Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
    Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
    Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.